JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF CABOZANTINIB PLUS NIVOLUMABIN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC RENAL CELL CARCINOMA
Not Applicable
Recruiting
- Conditions
- advanced or metastatic renal cell carcinoma
- Registration Number
- JPRN-UMIN000050778
- Lead Sponsor
- Kindai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1)Synchronous or metachronous (within 3 years) malignancies. 2)Surgery prior to initiation of cabozantinib + nivolumab combination therapy with incomplete wound healing or continued postoperative complications 3) Radiotherapy within 14 days before starting cabozantinib + nivolumab combination therapy. Must be fully recovered from radiotherapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ORR by cohort
- Secondary Outcome Measures
Name Time Method